首页 > 最新文献

Neurology Research International最新文献

英文 中文
Effectiveness and Adverse Effect of Intravenous Lacosamide in Nonconvulsive Status Epilepticus and Acute Repetitive Seizures in Children. 静脉注射拉科沙胺治疗儿童非惊厥性癫痫持续状态及急性反复发作的疗效及不良反应。
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-06-10 eCollection Date: 2018-01-01 DOI: 10.1155/2018/8432859
Monsicha Ngampoopun, Piradee Suwanpakdee, Nattapon Jaisupa, Charcrin Nabangchang

Nonconvulsive status epilepticus (NCSE) and acute repetitive seizures (ARS) are associated with significant morbidity and mortality. Due to the lack of randomized-controlled trials of intravenous antiepileptic drugs (AEDs) in these conditions, trials of a new generation of AEDs in this aspect are needed. A prospective interventional study was conducted in children under 18 years of age with NCSE or ARS who either had contraindication to or were refractory to first-line AEDs and received intravenous lacosamide. Demographic data, the efficacy of treatment, and adverse effects were recorded. Eleven patients with a median age of 11 years, predominantly female (72.7%), were enrolled. Average loading dose was 227 mg (8.3 mg/kg/dose) and average daily maintenance dose was 249 mg (4.6 mg/kg/dose). All patients (100%) experienced a reduction in seizure frequency within 24 hours. Eight of eleven patients (72.7%) experienced a reduction in seizure frequency of more than 50% by the end of the study, and one patient became seizure-free. In terms of adverse events, one patient had a bradycardia without prolongation of the PR interval. Interestingly, there was a case of neuronal ceroid lipofuscinosis in which a significant improvement in seizure control was achieved. The results indicate that intravenous lacosamide may be an alternative treatment for NCSE or ARS in children. To our knowledge, this is the first study on the use of intravenous lacosamide in Asian children. This study is registered to Thai Clinical Trials Registry (TCTR) and the trial registration number is TCTR20180508004.

非惊厥性癫痫持续状态(NCSE)和急性重复发作(ARS)与显著的发病率和死亡率相关。由于缺乏静脉注射抗癫痫药物(AEDs)在这些疾病中的随机对照试验,因此需要在这方面进行新一代抗癫痫药物的试验。一项前瞻性介入研究在18岁以下患有NCSE或ARS的儿童中进行,这些儿童对一线aed有禁忌症或难治性,并接受静脉注射拉科沙胺。记录人口统计学资料、治疗效果及不良反应。纳入11例患者,中位年龄为11岁,主要为女性(72.7%)。平均负荷剂量为227 mg (8.3 mg/kg/剂量),平均每日维持剂量为249 mg (4.6 mg/kg/剂量)。所有患者(100%)在24小时内癫痫发作频率降低。11名患者中有8名(72.7%)在研究结束时癫痫发作频率降低了50%以上,1名患者无癫痫发作。在不良事件方面,1例患者出现心动过缓,但PR间期未延长。有趣的是,有一个神经性ceroid脂褐质病的病例,在癫痫控制方面取得了显著的改善。结果表明静脉注射拉科沙胺可能是儿童NCSE或ARS的替代治疗方法。据我们所知,这是亚洲儿童静脉注射拉科沙胺的第一项研究。本研究已在泰国临床试验注册中心(TCTR)注册,试验注册号为TCTR20180508004。
{"title":"Effectiveness and Adverse Effect of Intravenous Lacosamide in Nonconvulsive Status Epilepticus and Acute Repetitive Seizures in Children.","authors":"Monsicha Ngampoopun,&nbsp;Piradee Suwanpakdee,&nbsp;Nattapon Jaisupa,&nbsp;Charcrin Nabangchang","doi":"10.1155/2018/8432859","DOIUrl":"https://doi.org/10.1155/2018/8432859","url":null,"abstract":"<p><p>Nonconvulsive status epilepticus (NCSE) and acute repetitive seizures (ARS) are associated with significant morbidity and mortality. Due to the lack of randomized-controlled trials of intravenous antiepileptic drugs (AEDs) in these conditions, trials of a new generation of AEDs in this aspect are needed. A prospective interventional study was conducted in children under 18 years of age with NCSE or ARS who either had contraindication to or were refractory to first-line AEDs and received intravenous lacosamide. Demographic data, the efficacy of treatment, and adverse effects were recorded. Eleven patients with a median age of 11 years, predominantly female (72.7%), were enrolled. Average loading dose was 227 mg (8.3 mg/kg/dose) and average daily maintenance dose was 249 mg (4.6 mg/kg/dose). All patients (100%) experienced a reduction in seizure frequency within 24 hours. Eight of eleven patients (72.7%) experienced a reduction in seizure frequency of more than 50% by the end of the study, and one patient became seizure-free. In terms of adverse events, one patient had a bradycardia without prolongation of the PR interval. Interestingly, there was a case of neuronal ceroid lipofuscinosis in which a significant improvement in seizure control was achieved. The results indicate that intravenous lacosamide may be an alternative treatment for NCSE or ARS in children. To our knowledge, this is the first study on the use of intravenous lacosamide in Asian children. This study is registered to Thai Clinical Trials Registry (TCTR) and the trial registration number is TCTR20180508004.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"8432859"},"PeriodicalIF":1.5,"publicationDate":"2018-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/8432859","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36293205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
The Early Outcomes of Nurse Case Management in Patients with Acute Ischemic Stroke Treated with Intravenous Recombinant Tissue Plasminogen Activator: A Prospective Randomized Controlled Trial. 静脉注射重组组织型纤溶酶原激活剂治疗急性缺血性脑卒中患者的护理病例管理的早期结果:一项前瞻性随机对照试验。
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-06-07 eCollection Date: 2018-01-01 DOI: 10.1155/2018/1717843
Urai Kummarg, Siriorn Sindhu, Sombat Muengtaweepongsa

Background: Intravenous recombinant tissue plasminogen activator (i.v. rt-PA) is the milestone treatment for patients with acute ischemic stroke. Stroke Fast Track (SFT) facilitates time reduction, guarantees safety, and promotes good clinical outcomes in i.v. rt-PA treatment. Nursing case management is a healthcare service providing clinical benefits in many specific diseases. The knowledge about the efficacy of a nurse case management for Stroke Fast Track is limited. We aim to study the effect of nurse case management on clinical outcomes in patients with acute ischemic stroke involving intravenous recombinant tissue plasminogen activator (i.v. rt-PA) treatment.

Methods: Seventy-six patients with acute ischemic stroke who received i.v. rt-PA treatment under Stroke Fast Track protocol of Thammasat University Hospital were randomized into two groups. One group was assigned to get standard care (control) while another group was assigned to get standard care under a nurse case management. The National Institute of Health Stroke Scale (NIHSS) at 24 hours after treatment between the control and the experimental groups was evaluated.

Results: Time from triage to treatment in the experimental group was significantly faster than in the control group (mean = 39.02 and 59.37 minutes, respectively; p=.001). The NIHSS at 24 hours after treatment in the nurse case management group was significantly improved as compared to the control group (p=.001). No symptomatic intracranial hemorrhage (sICH) was detected at 24 hours after onset in both groups.

Conclusion: The nurse case management should provide some benefits in the acute stroke system. Although the early benefit is demonstrated in our study, further studies are needed to ensure the long-term benefit and confirm its profit in patients with acute ischemic stroke.

背景:静脉注射重组组织型纤溶酶原激活剂(rt-PA)是急性缺血性卒中患者的里程碑式治疗。卒中快速通道(SFT)有助于减少时间,保证安全性,并促进静脉注射rt-PA治疗的良好临床结果。护理病例管理是一项医疗保健服务,为许多特定疾病提供临床效益。关于中风快速通道护士病例管理的有效性的知识是有限的。我们的目的是研究护理病例管理对急性缺血性脑卒中患者静脉注射重组组织纤溶酶原激活剂(i.v. rt-PA)治疗的临床结果的影响。方法:选取76例在法政大学医院脑卒中快速通道方案下接受静脉注射rt-PA治疗的急性缺血性脑卒中患者,随机分为两组。一组被分配接受标准治疗(对照组),而另一组被分配在护士病例管理下接受标准治疗。对对照组和试验组治疗后24小时的美国国立卫生研究院卒中量表(NIHSS)进行评估。结果:实验组从分诊到治疗的时间明显快于对照组(平均分别为39.02和59.37分钟);p =措施)。护理病例管理组治疗后24小时NIHSS较对照组显著改善(p=.001)。两组患者发病后24小时均未发现症状性颅内出血(siich)。结论:护理病例管理在急性脑卒中系统中发挥了一定的作用。虽然在我们的研究中证实了早期获益,但需要进一步的研究来确保长期获益,并确认其对急性缺血性脑卒中患者的益处。
{"title":"The Early Outcomes of Nurse Case Management in Patients with Acute Ischemic Stroke Treated with Intravenous Recombinant Tissue Plasminogen Activator: A Prospective Randomized Controlled Trial.","authors":"Urai Kummarg,&nbsp;Siriorn Sindhu,&nbsp;Sombat Muengtaweepongsa","doi":"10.1155/2018/1717843","DOIUrl":"https://doi.org/10.1155/2018/1717843","url":null,"abstract":"<p><strong>Background: </strong>Intravenous recombinant tissue plasminogen activator (i.v. rt-PA) is the milestone treatment for patients with acute ischemic stroke. Stroke Fast Track (SFT) facilitates time reduction, guarantees safety, and promotes good clinical outcomes in i.v. rt-PA treatment. Nursing case management is a healthcare service providing clinical benefits in many specific diseases. The knowledge about the efficacy of a nurse case management for Stroke Fast Track is limited. We aim to study the effect of nurse case management on clinical outcomes in patients with acute ischemic stroke involving intravenous recombinant tissue plasminogen activator (i.v. rt-PA) treatment.</p><p><strong>Methods: </strong>Seventy-six patients with acute ischemic stroke who received i.v. rt-PA treatment under Stroke Fast Track protocol of Thammasat University Hospital were randomized into two groups. One group was assigned to get standard care (control) while another group was assigned to get standard care under a nurse case management. The National Institute of Health Stroke Scale (NIHSS) at 24 hours after treatment between the control and the experimental groups was evaluated.</p><p><strong>Results: </strong>Time from triage to treatment in the experimental group was significantly faster than in the control group (mean = 39.02 and 59.37 minutes, respectively; p=.001). The NIHSS at 24 hours after treatment in the nurse case management group was significantly improved as compared to the control group (p=.001). No symptomatic intracranial hemorrhage (sICH) was detected at 24 hours after onset in both groups.</p><p><strong>Conclusion: </strong>The nurse case management should provide some benefits in the acute stroke system. Although the early benefit is demonstrated in our study, further studies are needed to ensure the long-term benefit and confirm its profit in patients with acute ischemic stroke.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"1717843"},"PeriodicalIF":1.5,"publicationDate":"2018-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/1717843","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36288324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Can Chaotic Analysis of Electroencephalogram Aid the Diagnosis of Encephalopathy? 脑电图混沌分析有助于脑病的诊断吗?
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-05-29 eCollection Date: 2018-01-01 DOI: 10.1155/2018/8192820
Jisu Elsa Jacob, Ajith Cherian, K Gopakumar, Thomas Iype, Doris George Yohannan, K P Divya

Chaotic analysis is a relatively novel area in the study of physiological signals. Chaotic features of electroencephalogram have been analyzed in various disease states like epilepsy, Alzheimer's disease, sleep disorders, and depression. All these diseases have primary involvement of the brain. Our study examines the chaotic parameters in metabolic encephalopathy, where the brain functions are involved secondary to a metabolic disturbance. Our analysis clearly showed significant lower values for chaotic parameters, correlation dimension, and largest Lyapunov exponent for EEG in patients with metabolic encephalopathy compared to normal EEG. The chaotic features of EEG have been shown in previous studies to be an indicator of the complexity of brain dynamics. The smaller values of chaotic features for encephalopathy suggest that normal complexity of brain function is reduced in encephalopathy. To the best knowledge of the authors, no similar work has been reported on metabolic encephalopathy. This finding may be useful to understand the neurobiological phenomena in encephalopathy. These chaotic features are then utilized as feature sets for Support Vector Machine classifier to identify cases of encephalopathy from normal healthy subjects yielding high values of accuracy. Thus, we infer that chaotic measures are EEG parameters sensitive to functional alterations of the brain, caused by encephalopathy.

混沌分析是生理信号研究中一个相对较新的领域。在癫痫、阿尔茨海默病、睡眠障碍和抑郁症等各种疾病状态下,脑电图的混沌特征已被分析。所有这些疾病都主要累及大脑。我们的研究检查了代谢性脑病的混沌参数,其中脑功能涉及继发于代谢紊乱。我们的分析清楚地显示,与正常脑电图相比,代谢性脑病患者脑电图的混沌参数、相关维数和最大Lyapunov指数显著降低。脑电图的混沌特征在以往的研究中已被证明是脑动力学复杂性的一个指标。脑病的混沌特征值越小,表明脑病的正常脑功能复杂性降低。据作者所知,没有关于代谢性脑病的类似研究报道。这一发现可能有助于了解脑病的神经生物学现象。然后将这些混沌特征用作支持向量机分类器的特征集,以从正常健康受试者中识别脑病病例,从而获得较高的准确性。因此,我们推断混沌测量是脑电图参数对脑病引起的脑功能改变敏感。
{"title":"Can Chaotic Analysis of Electroencephalogram Aid the Diagnosis of Encephalopathy?","authors":"Jisu Elsa Jacob,&nbsp;Ajith Cherian,&nbsp;K Gopakumar,&nbsp;Thomas Iype,&nbsp;Doris George Yohannan,&nbsp;K P Divya","doi":"10.1155/2018/8192820","DOIUrl":"https://doi.org/10.1155/2018/8192820","url":null,"abstract":"<p><p>Chaotic analysis is a relatively novel area in the study of physiological signals. Chaotic features of electroencephalogram have been analyzed in various disease states like epilepsy, Alzheimer's disease, sleep disorders, and depression. All these diseases have primary involvement of the brain. Our study examines the chaotic parameters in metabolic encephalopathy, where the brain functions are involved secondary to a metabolic disturbance. Our analysis clearly showed significant lower values for chaotic parameters, correlation dimension, and largest Lyapunov exponent for EEG in patients with metabolic encephalopathy compared to normal EEG. The chaotic features of EEG have been shown in previous studies to be an indicator of the complexity of brain dynamics. The smaller values of chaotic features for encephalopathy suggest that normal complexity of brain function is reduced in encephalopathy. To the best knowledge of the authors, no similar work has been reported on metabolic encephalopathy. This finding may be useful to understand the neurobiological phenomena in encephalopathy. These chaotic features are then utilized as feature sets for Support Vector Machine classifier to identify cases of encephalopathy from normal healthy subjects yielding high values of accuracy. Thus, we infer that chaotic measures are EEG parameters sensitive to functional alterations of the brain, caused by encephalopathy.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"8192820"},"PeriodicalIF":1.5,"publicationDate":"2018-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/8192820","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36308896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Neuropsychiatric Involvement in Juvenile-Onset Systemic Lupus Erythematosus. 青少年始发系统性红斑狼疮的神经精神参与。
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-05-29 eCollection Date: 2018-01-01 DOI: 10.1155/2018/2548142
Mohammad-Amin Khajezadeh, Gholamreza Zamani, Bobak Moazzami, Zahra Nagahi, Mahdie Mousavi-Torshizi, Vahid Ziaee

Objective: Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by multisystem involvement, including the nervous system. In the present study, we aimed to assess neuropsychiatric manifestations in juvenile-onset systemic lupus erythematosus (JSLE) in Iran.

Methods: One hundred and forty-six pediatric onset patients with SLE who had registered in our pediatric rheumatology database were evaluated prospectively and cross sectionally within 2013-2015. Data including sex, age, age at the time of diagnosis, age at the time of study, physical examination, laboratory review, and neuropsychiatric inventory were extracted from this database. Classification of neuropsychiatric JSLE was according to the 1999 American College of Rheumatology (ACR) neuropsychiatric manifestations of SLE case definitions.

Result: A total number of 41 patients with neuropsychiatric symptoms were selected. The patients' average age was 12.2 years. The most common neuropsychiatric symptoms were seizures, migraine, and depression. The mean age at the onset of symptoms was 10.2 ± 3 years. Mean follow-up period was 57±34 (range: 12-120) months. From 41 SLE patients, 18 (43.9) presented symptoms at the time of diagnosis. In thirteen (31.7%) patients, neurological symptoms were developed more than 1 year after SLE diagnosis. Headache was the most common feature (13%), followed by seizure (9.5%) and chorea (3.4%). Other neurological manifestations included cranial nerve involvement (0.7%), loss of consciousness (2.7%), and impaired deep tendon reflex neuropathy (2.5%). The least common neuropsychiatric JSLE manifestation was aseptic meningitis seen in only one patient (0.7%).

Conclusion: The presence of headache, mood disorders, psychosis, depression, and other neuropsychological manifestations in a patient with JSLE should prompt investigations into diagnosis of the primary nervous system involvement in order to reduce mortality and morbidity.

目的:系统性红斑狼疮(SLE)是一种复杂的自身免疫性疾病,以包括神经系统在内的多系统受累为特征。在本研究中,我们旨在评估伊朗青少年发病的系统性红斑狼疮(JSLE)的神经精神表现。方法:对2013-2015年在我们的儿童风湿病数据库中登记的146例小儿起病SLE患者进行前瞻性和横断面评估。数据包括性别、年龄、诊断时年龄、研究时年龄、体格检查、实验室检查和神经精神量表。JSLE的神经精神分类依据1999年美国风湿病学会(ACR)对SLE病例的神经精神表现定义。结果:共选入41例有神经精神症状的患者。患者的平均年龄为12.2岁。最常见的神经精神症状是癫痫发作、偏头痛和抑郁。平均发病年龄为10.2±3岁。平均随访57±34个月(范围:12 ~ 120个月)。41例SLE患者中,18例(43.9)在诊断时出现症状。在13例(31.7%)患者中,神经系统症状在SLE诊断后超过1年才出现。头痛是最常见的特征(13%),其次是癫痫发作(9.5%)和舞蹈病(3.4%)。其他神经学表现包括颅神经受累(0.7%)、意识丧失(2.7%)和深肌腱反射神经病受损(2.5%)。JSLE最不常见的神经精神表现是无菌性脑膜炎,仅见于1例患者(0.7%)。结论:JSLE患者出现头痛、情绪障碍、精神病、抑郁和其他神经心理表现时,应及时检查原发神经系统受累的诊断,以降低死亡率和发病率。
{"title":"Neuropsychiatric Involvement in Juvenile-Onset Systemic Lupus Erythematosus.","authors":"Mohammad-Amin Khajezadeh,&nbsp;Gholamreza Zamani,&nbsp;Bobak Moazzami,&nbsp;Zahra Nagahi,&nbsp;Mahdie Mousavi-Torshizi,&nbsp;Vahid Ziaee","doi":"10.1155/2018/2548142","DOIUrl":"https://doi.org/10.1155/2018/2548142","url":null,"abstract":"<p><strong>Objective: </strong>Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by multisystem involvement, including the nervous system. In the present study, we aimed to assess neuropsychiatric manifestations in juvenile-onset systemic lupus erythematosus (JSLE) in Iran.</p><p><strong>Methods: </strong>One hundred and forty-six pediatric onset patients with SLE who had registered in our pediatric rheumatology database were evaluated prospectively and cross sectionally within 2013-2015. Data including sex, age, age at the time of diagnosis, age at the time of study, physical examination, laboratory review, and neuropsychiatric inventory were extracted from this database. Classification of neuropsychiatric JSLE was according to the 1999 American College of Rheumatology (ACR) neuropsychiatric manifestations of SLE case definitions.</p><p><strong>Result: </strong>A total number of 41 patients with neuropsychiatric symptoms were selected. The patients' average age was 12.2 years. The most common neuropsychiatric symptoms were seizures, migraine, and depression. The mean age at the onset of symptoms was 10.2 ± 3 years. Mean follow-up period was 57±34 (range: 12-120) months. From 41 SLE patients, 18 (43.9) presented symptoms at the time of diagnosis. In thirteen (31.7%) patients, neurological symptoms were developed more than 1 year after SLE diagnosis. Headache was the most common feature (13%), followed by seizure (9.5%) and chorea (3.4%). Other neurological manifestations included cranial nerve involvement (0.7%), loss of consciousness (2.7%), and impaired deep tendon reflex neuropathy (2.5%). The least common neuropsychiatric JSLE manifestation was aseptic meningitis seen in only one patient (0.7%).</p><p><strong>Conclusion: </strong>The presence of headache, mood disorders, psychosis, depression, and other neuropsychological manifestations in a patient with JSLE should prompt investigations into diagnosis of the primary nervous system involvement in order to reduce mortality and morbidity.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"2548142"},"PeriodicalIF":1.5,"publicationDate":"2018-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/2548142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36308895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 26
The Perceived Social Stigma of People with Epilepsy with regard to the Question of Employability. 癫痫患者在就业能力问题上的社会污名。
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-05-13 eCollection Date: 2018-01-01 DOI: 10.1155/2018/4140508
Jéssica Lopes de Souza, Aline Scardoeli Faiola, Carmen Silvia Molleis Galego Miziara, Maria Luiza Giraldes de Manreza

Objective: To evaluate the perceived social stigma of people with epilepsy with regard to the question of employability.

Methods: A structured questionnaire was given to two groups of people with chronic diseases: those with epilepsy (study group) and those with heart disease (control group). The questions concerned employability.

Results: Having epilepsy was more strongly associated with higher unemployment rates (p < 0.0001); job layoffs (p = 0.001); being unfit to work (p < 0.0001); feeling shame for having the disease (p = 0.014); absence of partners (p = 0.026); and depression (p = 0.004). The tendency to hide their disease from their employers was similar for the two groups.

Conclusion: The age discrepancy between groups was an important limiting factor of this study. However, despite the limited number of participants and the age difference between the groups, there is no impediment in stating that people with epilepsy show high rates of unemployment, depression, and stigma.

目的:评价癫痫患者在就业问题上的社会耻辱感。方法:对癫痫患者(研究组)和心脏病患者(对照组)两组慢性疾病患者进行结构化问卷调查。这些问题与就业能力有关。结果:癫痫与高失业率的相关性更强(p < 0.0001);裁员(p = 0.001);不适合工作(p < 0.0001);对患病感到羞耻(p = 0.014);无伴侣(p = 0.026);抑郁(p = 0.004)。这两组人对雇主隐瞒病情的倾向是相似的。结论:组间年龄差异是本研究的重要限制因素。然而,尽管参与者人数有限,而且年龄组之间存在年龄差异,但毫无疑问,癫痫患者的失业率、抑郁率和耻辱感都很高。
{"title":"The Perceived Social Stigma of People with Epilepsy with regard to the Question of Employability.","authors":"Jéssica Lopes de Souza,&nbsp;Aline Scardoeli Faiola,&nbsp;Carmen Silvia Molleis Galego Miziara,&nbsp;Maria Luiza Giraldes de Manreza","doi":"10.1155/2018/4140508","DOIUrl":"https://doi.org/10.1155/2018/4140508","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the perceived social stigma of people with epilepsy with regard to the question of employability.</p><p><strong>Methods: </strong>A structured questionnaire was given to two groups of people with chronic diseases: those with epilepsy (study group) and those with heart disease (control group). The questions concerned employability.</p><p><strong>Results: </strong>Having epilepsy was more strongly associated with higher unemployment rates (<i>p</i> < 0.0001); job layoffs (<i>p</i> = 0.001); being unfit to work (<i>p</i> < 0.0001); feeling shame for having the disease (<i>p</i> = 0.014); absence of partners (<i>p</i> = 0.026); and depression (<i>p</i> = 0.004). The tendency to hide their disease from their employers was similar for the two groups.</p><p><strong>Conclusion: </strong>The age discrepancy between groups was an important limiting factor of this study. However, despite the limited number of participants and the age difference between the groups, there is no impediment in stating that people with epilepsy show high rates of unemployment, depression, and stigma.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"4140508"},"PeriodicalIF":1.5,"publicationDate":"2018-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/4140508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36189339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 22
Ethnicity Influences Corpus Callosum Dimensions. 种族对胼胝体尺寸的影响。
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-05-02 eCollection Date: 2018-01-01 DOI: 10.1155/2018/8916035
Hilda Nouri Hosseini, Mohammad Reza Mohammadi, Mohsen Aarabi, Narges Mohammadi, Mohammad Jafar Golalipour

Background and objective: Corpus callosum (CC), the main white matter cable which connects two hemispheres of brain, is important in special procedures such as stereotaxic surgeries vary in size, in different populations. Determination of possible size differences in ethnical groups has special values.

Patients and methods: The size of the CC on midsagittal view was determined in 76 normal male subjects using MRI of brain hemispheres in northern Iran. The size of rostrum, body, splenium, length, and height of CC was measured for each subject. The width of the body of the corpus callosum (B), the anterior to posterior length (L) and the maximum height (H) of the corpus callosum, and ratios B/L and B/H were also calculated.

Results: The longitudinal dimensions of the CC were 70.21 mm and 74.05 mm in native Fars and Turkmens, respectively (P < 0.05). The heights were 25 mm and 25.75 mm in native Fars and Turkmen subjects, respectively. The width of CC in Turkmen people was significantly higher than native Fars people (P < 0.05). The Evans index in Turkmen group (0.314) was significantly higher than in native Fars (0.3). The B/L and B/H ratios were nonsignificantly different between two groups.

Conclusion: The CC parameters vary in different ethnical groups in northern Iran.

背景与目的:胼胝体(CC)是连接大脑两个半球的主要白质电缆,在立体定向手术等特殊手术中具有重要作用。确定种族群体中可能存在的体型差异具有特殊的价值。患者和方法:对伊朗北部地区76例正常男性受试者进行了中矢状面核磁共振成像(MRI)检查。测量每位受试者的体表、体、脾的大小、CC的长度和高度。计算胼胝体体宽(B)、前后长度(L)、最大高度(H)及B/L、B/H比值。结果:土生法尔人和土生土库曼人CC纵向尺寸分别为70.21 mm和74.05 mm (P < 0.05)。法尔斯人和土库曼人的身高分别为25 mm和25.75 mm。土库曼人CC的宽度显著高于当地法尔斯人(P < 0.05)。土库曼人Evans指数(0.314)显著高于当地法尔人(0.3)。B/L和B/H比值在两组间无显著差异。结论:伊朗北部不同民族CC参数存在差异。
{"title":"Ethnicity Influences Corpus Callosum Dimensions.","authors":"Hilda Nouri Hosseini,&nbsp;Mohammad Reza Mohammadi,&nbsp;Mohsen Aarabi,&nbsp;Narges Mohammadi,&nbsp;Mohammad Jafar Golalipour","doi":"10.1155/2018/8916035","DOIUrl":"https://doi.org/10.1155/2018/8916035","url":null,"abstract":"<p><strong>Background and objective: </strong>Corpus callosum (CC), the main white matter cable which connects two hemispheres of brain, is important in special procedures such as stereotaxic surgeries vary in size, in different populations. Determination of possible size differences in ethnical groups has special values.</p><p><strong>Patients and methods: </strong>The size of the CC on midsagittal view was determined in 76 normal male subjects using MRI of brain hemispheres in northern Iran. The size of rostrum, body, splenium, length, and height of CC was measured for each subject. The width of the body of the corpus callosum (<i>B</i>), the anterior to posterior length (<i>L</i>) and the maximum height (<i>H</i>) of the corpus callosum, and ratios <i>B</i>/<i>L</i> and <i>B</i>/<i>H</i> were also calculated.</p><p><strong>Results: </strong>The longitudinal dimensions of the CC were 70.21 mm and 74.05 mm in native Fars and Turkmens, respectively (<i>P</i> < 0.05). The heights were 25 mm and 25.75 mm in native Fars and Turkmen subjects, respectively. The width of CC in Turkmen people was significantly higher than native Fars people (<i>P</i> < 0.05). The Evans index in Turkmen group (0.314) was significantly higher than in native Fars (0.3). The <i>B</i>/<i>L</i> and <i>B</i>/<i>H</i> ratios were nonsignificantly different between two groups.</p><p><strong>Conclusion: </strong>The CC parameters vary in different ethnical groups in northern Iran.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"8916035"},"PeriodicalIF":1.5,"publicationDate":"2018-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/8916035","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36181979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Risk Factors Associated with Severity of Nongenetic Intellectual Disability (Mental Retardation) among Children Aged 2-18 Years Attending Kenyatta National Hospital. 肯雅塔国家医院2-18岁儿童非遗传性智力残疾(智力迟钝)严重程度相关的危险因素
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-04-18 eCollection Date: 2018-01-01 DOI: 10.1155/2018/6956703
Mathieu Nemerimana, Margaret Njambi Chege, Eunice Ajode Odhiambo

Background: Many of the nongenetic causal risk factors of intellectual disability (ID) can be prevented if they are identified early. There is paucity on information regarding potential risk factors associated with this condition in Kenya. This study aimed to establish risk factors associated with severity of nongenetic intellectual disability (ID) among children presenting with this condition at Kenyatta National Hospital (KNH).

Methods: A hospital-based cross-sectional study was conducted over the period between March and June 2017 in pediatric and child/youth mental health departments of Kenyatta National Hospital (KNH), Kenya. It included children aged 2-18 years diagnosed with ID without underlying known genetic cause.

Results: Of 97 patients with nongenetic ID, 24% had mild ID, 40% moderate, 23% severe-profound, and 10% unspecified ID. The mean age of children was 5.6 (±3.6) years. Male children were predominant (62%). Three independent factors including "labor complications" [AOR = 9.45, 95% CI = 1.23-113.29, P = 0.036], "admission to neonatal intensive care unit" [AOR = 8.09, 95% CI = 2.11-31.07, P = 0.002], and "cerebral palsy" [AOR = 21.18, CI = 4.18-107.40, P ≤ 0.001] were significantly associated with increased risk of severe/profound nongenetic ID.

Conclusion: The present study findings suggest that perinatal complications as well as postnatal insults are associated with increased risk of developing severe-profound intellectual disability, implying that this occurrence may be reduced with appropriate antenatal, perinatal, and neonatal healthcare interventions.

背景:许多智力残疾(ID)的非遗传致病风险因素如果及早发现是可以预防的。肯尼亚缺乏与该病相关的潜在风险因素的信息。本研究旨在确定在肯雅塔国家医院(KNH)就诊的儿童中与非遗传性智力残疾(ID)严重程度相关的危险因素。方法:2017年3月至6月期间,在肯尼亚肯雅塔国家医院(KNH)的儿科和儿童/青少年精神卫生部门进行了一项基于医院的横断面研究。它包括2-18岁的儿童,被诊断患有ID,但没有潜在的已知遗传原因。结果:97例非遗传性ID患者中,24%为轻度ID, 40%为中度ID, 23%为重度ID, 10%为未明确ID。患儿平均年龄5.6(±3.6)岁。男童占多数(62%)。“分娩并发症”[AOR = 9.45, 95% CI = 1.23 ~ 113.29, P = 0.036]、“入院新生儿重症监护病房”[AOR = 8.09, 95% CI = 2.11 ~ 31.07, P = 0.002]和“脑瘫”[AOR = 21.18, CI = 4.18 ~ 107.40, P≤0.001]三个独立因素与重度/重度非遗传性ID风险增加显著相关。结论:目前的研究结果表明,围产期并发症以及出生后的侮辱与发生严重-深度智力残疾的风险增加有关,这意味着通过适当的产前、围产期和新生儿保健干预可以降低这种发生率。
{"title":"Risk Factors Associated with Severity of Nongenetic Intellectual Disability (Mental Retardation) among Children Aged 2-18 Years Attending Kenyatta National Hospital.","authors":"Mathieu Nemerimana,&nbsp;Margaret Njambi Chege,&nbsp;Eunice Ajode Odhiambo","doi":"10.1155/2018/6956703","DOIUrl":"https://doi.org/10.1155/2018/6956703","url":null,"abstract":"<p><strong>Background: </strong>Many of the nongenetic causal risk factors of intellectual disability (ID) can be prevented if they are identified early. There is paucity on information regarding potential risk factors associated with this condition in Kenya. This study aimed to establish risk factors associated with severity of nongenetic intellectual disability (ID) among children presenting with this condition at Kenyatta National Hospital (KNH).</p><p><strong>Methods: </strong>A hospital-based cross-sectional study was conducted over the period between March and June 2017 in pediatric and child/youth mental health departments of Kenyatta National Hospital (KNH), Kenya. It included children aged 2-18 years diagnosed with ID without underlying known genetic cause.</p><p><strong>Results: </strong>Of 97 patients with nongenetic ID, 24% had mild ID, 40% moderate, 23% severe-profound, and 10% unspecified ID. The mean age of children was 5.6 (±3.6) years. Male children were predominant (62%). Three independent factors including \"labor complications\" [AOR = 9.45, 95% CI = 1.23-113.29, <i>P</i> = 0.036], \"admission to neonatal intensive care unit\" [AOR = 8.09, 95% CI = 2.11-31.07, <i>P</i> = 0.002], and \"cerebral palsy\" [AOR = 21.18, CI = 4.18-107.40, <i>P</i> ≤ 0.001] were significantly associated with increased risk of severe/profound nongenetic ID.</p><p><strong>Conclusion: </strong>The present study findings suggest that perinatal complications as well as postnatal insults are associated with increased risk of developing severe-profound intellectual disability, implying that this occurrence may be reduced with appropriate antenatal, perinatal, and neonatal healthcare interventions.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"6956703"},"PeriodicalIF":1.5,"publicationDate":"2018-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/6956703","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36177998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patient with Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial. 大剂量和小剂量辛伐他汀对急性缺血性脑卒中患者血管氧化应激和神经功能预后的疗效:一项随机、双盲、平行对照试验。
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-04-18 eCollection Date: 2018-01-01 DOI: 10.1155/2018/7268924
Nattaphol Uransilp, Pannawat Chaiyawatthanananthn, Sombat Muengtaweepongsa

Backgrounds: Stroke is the leading cause of death and long-term disability. Oxidative stress is elevated during occurrence of acute ischemic stroke (AIS). Soluble LOX-1 (sLOX-1) and NO are used as biomarkers for vascular oxidative stress that can reflect stabilization of atherosclerotic plaque. Previous study showed that simvastatin can reduce oxidative stress and LOX-1 expression.

Objectives: To evaluate neurological outcomes and serum sLOX-1 and NO levels in patients with AIS treatment with low dose 10 mg/day and high dose 40 mg/day of simvastatin.

Methods: 65 patients with AIS within 24 hours after onset were randomized to treatment with simvastatin 10 mg/day or 40 mg/day for 90 days. Personal data and past history of all patients were recorded at baseline. The blood chemistries were measured by standard laboratory techniques. Serum sLOX-1 and NO levels and neurological outcomes including NIHSS, mRS, and Barthel index were tested at baseline and Day 90 after simvastatin therapy.

Results: Baseline characteristics were not significantly different in both groups except history of hypertension. Serum sLOX-1 and NO levels significantly reduce in both groups (sLOX-1 = 1.19 ± 0.47 and 0.98 ± 0.37 ng/ml; NO = 49.28 ± 7.21 and 46.59 ± 9.36 μmol/l) in 10 mg/day and 40 mg/day simvastatin groups, respectively. Neurological outcomes including NIHSS, mRS, and Barthel index significantly improve in both groups. However, no difference in NO level and neurological outcomes was found at 90 days after treatment as compared between low dose 10 mg/day and high dose 40 mg/day of simvastatin.

Conclusion: High-dose simvastatin might be helpful to reduce serum sLOX-1. But no difference in clinical outcomes was found between high- and low-dose simvastatin. Further more intensive clinical trial is needed to confirm the appropriate dosage of simvastatin in patients with acute ischemic stroke. This trial is registered with ClinicalTrials.gov ID: NCT03402204.

背景:中风是导致死亡和长期残疾的主要原因。急性缺血性中风(AIS)发生时氧化应激升高。可溶性 LOX-1(sLOX-1)和 NO 是血管氧化应激的生物标志物,可反映动脉粥样硬化斑块的稳定性。先前的研究表明,辛伐他汀可降低氧化应激和 LOX-1 的表达:方法:65例发病24小时内的AIS患者随机接受辛伐他汀10毫克/天或40毫克/天的治疗,为期90天。所有患者的个人资料和既往病史均在基线时记录。采用标准实验室技术测量血液化学成分。在辛伐他汀治疗后的基线和第90天检测血清sLOX-1和NO水平以及神经系统结果,包括NIHSS、mRS和Barthel指数:结果:除高血压病史外,两组患者的基线特征无明显差异。辛伐他汀10毫克/天组和40毫克/天组的血清sLOX-1和NO水平分别明显降低(sLOX-1=1.19±0.47和0.98±0.37纳克/毫升;NO=49.28±7.21和46.59±9.36微摩尔/升)。两组患者的神经功能结果(包括 NIHSS、mRS 和 Barthel 指数)均明显改善。然而,与低剂量辛伐他汀(10 毫克/天)和高剂量辛伐他汀(40 毫克/天)相比,在治疗 90 天后,NO 水平和神经功能结果均无差异:结论:大剂量辛伐他汀可能有助于降低血清sLOX-1。结论:高剂量辛伐他汀可能有助于降低血清 sLOX-1,但高剂量和低剂量辛伐他汀的临床结果没有差异。需要进一步开展更深入的临床试验,以确定辛伐他汀在急性缺血性脑卒中患者中的合适剂量。该试验已在 ClinicalTrials.gov ID:NCT03402204。
{"title":"Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patient with Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial.","authors":"Nattaphol Uransilp, Pannawat Chaiyawatthanananthn, Sombat Muengtaweepongsa","doi":"10.1155/2018/7268924","DOIUrl":"10.1155/2018/7268924","url":null,"abstract":"<p><strong>Backgrounds: </strong>Stroke is the leading cause of death and long-term disability. Oxidative stress is elevated during occurrence of acute ischemic stroke (AIS). Soluble LOX-1 (sLOX-1) and NO are used as biomarkers for vascular oxidative stress that can reflect stabilization of atherosclerotic plaque. Previous study showed that simvastatin can reduce oxidative stress and LOX-1 expression.</p><p><strong>Objectives: </strong>To evaluate neurological outcomes and serum sLOX-1 and NO levels in patients with AIS treatment with low dose 10 mg/day and high dose 40 mg/day of simvastatin.</p><p><strong>Methods: </strong>65 patients with AIS within 24 hours after onset were randomized to treatment with simvastatin 10 mg/day or 40 mg/day for 90 days. Personal data and past history of all patients were recorded at baseline. The blood chemistries were measured by standard laboratory techniques. Serum sLOX-1 and NO levels and neurological outcomes including NIHSS, mRS, and Barthel index were tested at baseline and Day 90 after simvastatin therapy.</p><p><strong>Results: </strong>Baseline characteristics were not significantly different in both groups except history of hypertension. Serum sLOX-1 and NO levels significantly reduce in both groups (sLOX-1 = 1.19 ± 0.47 and 0.98 ± 0.37 ng/ml; NO = 49.28 ± 7.21 and 46.59 ± 9.36 <i>μ</i>mol/l) in 10 mg/day and 40 mg/day simvastatin groups, respectively. Neurological outcomes including NIHSS, mRS, and Barthel index significantly improve in both groups. However, no difference in NO level and neurological outcomes was found at 90 days after treatment as compared between low dose 10 mg/day and high dose 40 mg/day of simvastatin.</p><p><strong>Conclusion: </strong>High-dose simvastatin might be helpful to reduce serum sLOX-1. But no difference in clinical outcomes was found between high- and low-dose simvastatin. Further more intensive clinical trial is needed to confirm the appropriate dosage of simvastatin in patients with acute ischemic stroke. This trial is registered with ClinicalTrials.gov ID: NCT03402204.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"7268924"},"PeriodicalIF":1.5,"publicationDate":"2018-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36177999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Depressive Symptoms in Individuals after Stroke in a Home-Based Rehabilitation Setting. 以家庭为基础的康复环境中中风后个体的抑郁症状
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-04-11 eCollection Date: 2018-01-01 DOI: 10.1155/2018/1621830
Julianne Vermeer, Amanda McIntyre, Shannon Janzen, Danielle Rice, Laura Allen, David Ure, Robert Teasell

Poststroke depression has been shown to affect rehabilitation progress. This study evaluated patients after stroke who actively participated in a home-based rehabilitation program to determine variables that correlated with depressive symptoms in this population. A retrospective review of patients who were provided rehabilitation by Community Stroke Rehabilitation Team clinicians between January 1, 2009, and September 30, 2015, was completed. Logistic regression analysis was conducted to determine which demographic and outcome variables (Functional Independence Measure [FIM™] and Reintegration to Normal Living Index [RNLI]) were independently associated with depressive symptoms, as defined by Patient Health Questionnaire (PHQ-9) scores. 889 patients (53.2% male, mean age = 69.8 years) were included. Based on PHQ-9 scores, 89.7% of patients presented with no or mild depressive symptoms (PHQ-9 < 10) and 10.3% were considered to have moderate to severe depressive symptoms (PHQ-9 ≥ 10). The regression demonstrated that referral from outpatient, community care access centre, or community settings (OR = 1.89, p = 0.04), low RNLI scores (OR = 0.92; p = 0.001), and younger age (OR = 0.96; p < 0.001) predicted patients having moderate to severe depressive symptoms. Given the impact of poststroke depression on rehabilitation, clinicians should consider the potential impact of referral source, community reintegration, and age when monitoring and treating depressive symptoms.

中风后抑郁已被证明会影响康复进程。本研究评估了中风后积极参与家庭康复计划的患者,以确定与该人群抑郁症状相关的变量。对2009年1月1日至2015年9月30日期间由社区卒中康复团队临床医生提供康复治疗的患者进行回顾性分析。采用Logistic回归分析来确定哪些人口统计学和结局变量(功能独立性测量[FIM™]和重返正常生活指数[RNLI])与患者健康问卷(PHQ-9)评分定义的抑郁症状独立相关。共纳入889例患者,其中男性53.2%,平均年龄69.8岁。根据PHQ-9评分,89.7%的患者无或轻度抑郁症状(PHQ-9 < 10), 10.3%的患者被认为有中度至重度抑郁症状(PHQ-9≥10)。回归显示,来自门诊、社区护理中心或社区环境的转诊(or = 1.89, p = 0.04)、低RNLI评分(or = 0.92;p = 0.001),年龄越小(OR = 0.96;P < 0.001)预测患者有中度至重度抑郁症状。鉴于脑卒中后抑郁对康复的影响,临床医生在监测和治疗抑郁症状时应考虑转诊来源、社区重新融入和年龄的潜在影响。
{"title":"Depressive Symptoms in Individuals after Stroke in a Home-Based Rehabilitation Setting.","authors":"Julianne Vermeer,&nbsp;Amanda McIntyre,&nbsp;Shannon Janzen,&nbsp;Danielle Rice,&nbsp;Laura Allen,&nbsp;David Ure,&nbsp;Robert Teasell","doi":"10.1155/2018/1621830","DOIUrl":"https://doi.org/10.1155/2018/1621830","url":null,"abstract":"<p><p>Poststroke depression has been shown to affect rehabilitation progress. This study evaluated patients after stroke who actively participated in a home-based rehabilitation program to determine variables that correlated with depressive symptoms in this population. A retrospective review of patients who were provided rehabilitation by Community Stroke Rehabilitation Team clinicians between January 1, 2009, and September 30, 2015, was completed. Logistic regression analysis was conducted to determine which demographic and outcome variables (Functional Independence Measure [FIM™] and Reintegration to Normal Living Index [RNLI]) were independently associated with depressive symptoms, as defined by Patient Health Questionnaire (PHQ-9) scores. 889 patients (53.2% male, mean age = 69.8 years) were included. Based on PHQ-9 scores, 89.7% of patients presented with no or mild depressive symptoms (PHQ-9 < 10) and 10.3% were considered to have moderate to severe depressive symptoms (PHQ-9 ≥ 10). The regression demonstrated that referral from outpatient, community care access centre, or community settings (OR = 1.89, <i>p</i> = 0.04), low RNLI scores (OR = 0.92; <i>p</i> = 0.001), and younger age (OR = 0.96; <i>p</i> < 0.001) predicted patients having moderate to severe depressive symptoms. Given the impact of poststroke depression on rehabilitation, clinicians should consider the potential impact of referral source, community reintegration, and age when monitoring and treating depressive symptoms.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"1621830"},"PeriodicalIF":1.5,"publicationDate":"2018-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/1621830","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36177997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Number of Repetitions and Number of Hours of Shaping Practice during Constraint-Induced Movement Therapy: A Randomized Controlled Trial. 约束诱导运动治疗中重复次数和塑形练习小时数的影响:一项随机对照试验。
IF 1.5 Q4 NEUROSCIENCES Pub Date : 2018-04-02 eCollection Date: 2018-01-01 DOI: 10.1155/2018/5496408
Auwal Abdullahi

Background: Constraint-induced movement therapy (CIMT) is effective in improving motor outcomes after stroke. However, its existing protocols are resource-intensive and difficult to implement. The aim of this study is to design an easier CIMT protocol using number of repetitions of shaping practice.

Method: The study design was randomized controlled trial. Participants within 4 weeks after stroke were recruited at Murtala Muhammad Specialist Hospital. They were randomly assigned to groups A, B, C, and D. Group A received 3 hours of traditional therapy. Groups B, C, and D received modified CIMT consisting of 3 hours of shaping practice per session, 300 repetitions of shaping practice in 3 sessions, and 600 repetitions of shaping practice in 3 sessions per day, respectively, and constraint for 90% of the waking hours. All treatment protocols were administered 5 times per week for 4 weeks. The primary outcome was measured using upper limb Fugl-Meyer assessment, while the secondary outcome was measured using motor activity log, Wolf Motor Function Test, and upper limb self-efficacy test at baseline, 2 weeks, and 4 weeks after intervention.

Result: There were 48 participants 4 weeks after intervention. The result showed that there was no significant difference between groups at baseline (p > 0.05). Within-group improvements attained minimal clinically important difference (MCID) in modified CIMT and 300 repetitions and 600 repetitions groups.

Conclusion: Number of repetitions of shaping practice significantly improved motor function, real-world arm use, and upper limb self-efficacy after stroke. Therefore, it seems to be a simple alternative for the use of number of hours.

Trial registration: This trial is registered with Pan African Clinical Trial Registry (registration number: PACTR201610001828172) (date of registration: 21/10/2016).

背景:约束诱导运动疗法(CIMT)可有效改善脑卒中后的运动预后。然而,现有的协议资源密集,难以实现。本研究的目的是设计一个更容易的CIMT协议使用整形实践的重复次数。方法:采用随机对照试验设计。中风后4周内的参与者在穆尔塔拉穆罕默德专科医院招募。随机分为A、B、C、d组。A组常规治疗3小时。B组、C组和D组接受改良的CIMT,包括每节3小时的塑形练习,每天3节300次的塑形练习,每天3节600次的塑形练习,并在90%的清醒时间内进行约束。所有治疗方案均为每周5次,持续4周。主要结局采用上肢Fugl-Meyer评估测量,次要结局采用运动活动日志、Wolf运动功能测试和上肢自我效能测试在基线、干预后2周和4周测量。结果:干预4周后,共有48名参与者。结果显示,两组在基线时无显著差异(p > 0.05)。改良CIMT组、300次重复组和600次重复组的组内改善达到最小的临床重要差异(MCID)。结论:塑形练习次数显著改善脑卒中后运动功能、实际手臂使用和上肢自我效能。因此,这似乎是一个简单的替代使用的小时数。试验注册:本试验已在Pan African Clinical Trial Registry注册(注册号:PACTR201610001828172)(注册日期:21/10/2016)。
{"title":"Effects of Number of Repetitions and Number of Hours of Shaping Practice during Constraint-Induced Movement Therapy: A Randomized Controlled Trial.","authors":"Auwal Abdullahi","doi":"10.1155/2018/5496408","DOIUrl":"https://doi.org/10.1155/2018/5496408","url":null,"abstract":"<p><strong>Background: </strong>Constraint-induced movement therapy (CIMT) is effective in improving motor outcomes after stroke. However, its existing protocols are resource-intensive and difficult to implement. The aim of this study is to design an easier CIMT protocol using number of repetitions of shaping practice.</p><p><strong>Method: </strong>The study design was randomized controlled trial. Participants within 4 weeks after stroke were recruited at Murtala Muhammad Specialist Hospital. They were randomly assigned to groups A, B, C, and D. Group A received 3 hours of traditional therapy. Groups B, C, and D received modified CIMT consisting of 3 hours of shaping practice per session, 300 repetitions of shaping practice in 3 sessions, and 600 repetitions of shaping practice in 3 sessions per day, respectively, and constraint for 90% of the waking hours. All treatment protocols were administered 5 times per week for 4 weeks. The primary outcome was measured using upper limb Fugl-Meyer assessment, while the secondary outcome was measured using motor activity log, Wolf Motor Function Test, and upper limb self-efficacy test at baseline, 2 weeks, and 4 weeks after intervention.</p><p><strong>Result: </strong>There were 48 participants 4 weeks after intervention. The result showed that there was no significant difference between groups at baseline (<i>p</i> > 0.05). Within-group improvements attained minimal clinically important difference (MCID) in modified CIMT and 300 repetitions and 600 repetitions groups.</p><p><strong>Conclusion: </strong>Number of repetitions of shaping practice significantly improved motor function, real-world arm use, and upper limb self-efficacy after stroke. Therefore, it seems to be a simple alternative for the use of number of hours.</p><p><strong>Trial registration: </strong>This trial is registered with Pan African Clinical Trial Registry (registration number: PACTR201610001828172) (date of registration: 21/10/2016).</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":"2018 ","pages":"5496408"},"PeriodicalIF":1.5,"publicationDate":"2018-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/5496408","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36137316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 34
期刊
Neurology Research International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1